SEP 10, 2026 · PHASE 3 TRIAL
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
ClinicalTrials.gov
This is a Phase 3 trial registry record with no posted results; the study is actively enrolling to establish PK bioequivalence and efficacy similarity of a proposed biosimilar, making it an ongoing comparative effectiveness study without outcome data.
Reported
Planned enrollment726
PhasePHASE 3
Primary outcome 1Pharmacokinetic bioequivalence of MB12, EU-…